← Back to Patent Explorer
US4791131A Expired / Lapsed US ⏱️ 0.0 years remaining

Analgesic and antiinflammatory 1-acyl-2-oxindole-3-carboxamides

Assignee: Pfizer Inc
•
Filing: 1987-12-31
•
Granted: 1988-12-13
•
Expires: 2007-12-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Certain new 2-oxindole-3-carboxamide compounds having an acyl substituent at the 1-position are inhibitors of the cyclooxygenase (CO) and lipoxygenase (LO) enzymes, and are useful as analgesic and anti-inflammatory agents in mammalian subjects. In particular, the compounds of the invention are useful for acute administration for ameliorating or eliminating pain in human subjects recovering from surgery or trauma, and also for chronic administration for alleviating the symptoms of chronic diseases, such as rheumatoid arthritis and osteoarthritis, in human subjects.

Inventors

  • 👤 Saul B. Kadin

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 16:20
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; C07D209/00; C07D209/02; C07D209/04; C07D209/30; C07D209/42; C07D409/00; C07D409/02; C07D409/12; C07D417/00; C07D417/02; C07D417/12; C07D491/00; C07D491/02; C07D491/04

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 82 words
A 1-acyl-2-oxindole-3-carboxamide compound of the formula ##STR10## and the pharmaceutically-acceptable base salts thereof; wherein X and Y are each selected from the group consisting of hydrogen, fluoro, chloro, bormo, trifluoromethyl and alkyl having 1 to 4 carbons; R 1 is selected from the group consisting of heterocyclic, mono-methyl heterocyclic, furymethyl and thienylmethyl; wherein said heterocyclic is selected form the group consisting of pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl and isoxazolyl; and R 2 is alkyl having 1 to 6 carbons.
Claim 2
Dependent Claim 82 words
A 1-acyl-2-oxindole-3-carboxamide compound of the formula ##STR10## and the pharmaceutically-acceptable base salts thereof; wherein X and Y are each selected from the group consisting of hydrogen, fluoro, chloro, bormo, trifluoromethyl and alkyl having 1 to 4 carbons; R 1 is selected from the group consisting of heterocyclic, mono-methyl heterocyclic, furymethyl and thienylmethyl; wherein said heterocyclic is selected form the group consisting of pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl and isoxazolyl; and R 2 is alkyl having 1 to 6 carbons.
Claim 3
Dependent Claim 13 words
A compound according to claim 1, wherein R 1 is furylmethyl or thienylmethyl.
Claim 4
Dependent Claim 11 words
A compound according to claim 2, wherein R 2 is methyl.
Claim 5
Dependent Claim 16 words
A compound according to claim 1, wherein R 1 is said heterocyclic or said mono-methyl heterocyclic.
Claim 6
Dependent Claim 18 words
The compound according to claim 3, wherein X and Y are each hydrogen and R 1 is 2-thienylmethyl.
Claim 7
Dependent Claim 18 words
The compound according to claim 4, wherein X is 5-chloro, Y is hydrogen and R 1 is 2-pyridyl.
Claim 8
Dependent Claim 37 words
A pharmaceutical composition, which comprises a pharmaceutically-acceptable carrier and a 1-acyl-2-oxindole-3-carboxamide compound according to claim 1, and wherein the weight ratio of the pharmaceutically-acceptable carrier to the 1-acyl-2-oxindole-3-carboxamide compound is in the range from 1:4 to 4:1.
Claim 9
Dependent Claim 31 words
A method of eliciting an analgesic response in a mammalian subject, which comprises administering to said mammalian subject an analgesic response eliciting amount of a 1-acyl-2-oxindole-3-carboxamide compound according to claim 1.
Claim 10
Dependent Claim 31 words
A method of treating an inflammatory disease in a mammalian subject, which comprises administering to said mammalian subject an inflammatory disease treating amount of a 1-acyl-2-oxindole-3-carboxamide compound according to claim 1.

References Cited (Backward Citations)

US3190889A Cited
US3632587A Cited
US3634453A Cited
US4569942A Cited
US4730004A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-12-13 1992-06-13 1992-12-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-12-13 1996-06-13 1996-12-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-12-13 2000-06-13 2000-12-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag